Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: Our long-term clinical experience (GOIM study)

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Adamo, V ^a   Franchina, T ^a   Adamo, B ^a   Ferraro, G ^a   Rossello, R ^a   Saccà, M Maugeri ^a   Scibilia, C ^b   Valerio, M R ^b   Russo, A ^b  

^a Medical Oncology and Integrated Therapies Unit   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cardiac safety; Clinical experienceHheavily pretreated women; Metastatic breast cancer; Retrospective analysis; Trastuzumab

Indexed keywords

AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; BILIRUBIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SOFT TISSUE METASTASIS; TACHYCARDIA; VISCERAL METASTASIS; ARTICLE; BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; DRUG TOXICITY; METASTASIS; MIDDLE AGED; PATHOLOGY; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG TOXICITY; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 35748940673     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm217     Document Type: Conference Paper

References (25)

1. Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 2006; 6: 63.
2. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19(10): 2722-2730.
3. Tokunaga E, Oki E, Nishida K et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006; 11(3): 199-208.
4. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000; 27: 21-25; 92-100.
5. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of Herceptin (trastuzumab, humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC). Breast Cancer Res Treat 1998; 50: 232 (Abstr 21).
6. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
7. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
8. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
9. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
10. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004; 13: 173-183.
11. Untch M, Eidtmann H, du Bois A et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: Results of a phase I trial. Eur J Cancer 2004; 40: 988-997.
12. Baselga J, Climent MA, Lluch A et al. Results of a phase II study of liposomal doxorubicin (Myocet) in combination with weekly paclitaxel and trastuzumab (Herceptin) in patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC). Eur J Cancer 2004; 2 ((Suppl)): 132.
13. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-2895.
14. Pegram MD, Pienkowski T, Northfelt DW et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER-2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-769.
15. Robert N, Leyland-Jones B, Asmar L et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76: 37.
16. Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carbopaltin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-2792.
17. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
18. Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 2006; 11 (Suppl 1): 34-41.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
20. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: Version 2.0 an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
21. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5: 52-58.
22. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003; 4: 120-125.
23. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
24. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101(4): 810-816.
25. Yau T, Swanton C, Chua S et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006; 45: 196-201.